Type 1 diabetes diagnosis is missed less frequently when patients present during childhood or adolescence, but unlike in adults, misdiagnosis in childhood is associated with an increased likelihood of diabetic ketoacidosis.
Children with type 1 diabetes have worse education and health outcomes than their peers.
Lexicon Pharmaceuticals announced new data from the phase 3 inTandem1 and inTandem2 studies of sotagliflozin in adult patients with type 1 diabetes.
Maternal blood glucose levels and body mass index are the most important modifiable risk factors for stillbirth in women with pre-pregnancy diabetes.
The FDA has granted Breakthrough Therapy designation to teplizumab (PRV-031; Provention Bio), for the prevention or delay of clinical T1D in those at risk of developing the disease.
In young patients with type 1 diabetes, phenotypes of body mass index and glycemic control are associated with patterns of early diabetes complications.
Researchers aimed to determine the optimal BP threshold to minimize the risk for coronary artery disease events in young patients with childhood-onset T1D.
Checkpoint inhibitor-associated autoimmune diabetes (CIADM) is a distinct pathophysiologic entity from type 1 diabetes.
Dapagliflozin was recently approved for T1D in Europe and Japan.
Measurement of serum apolipoprotein levels in apolipoprotein-defined lipoprotein subclasses may have an important role in predicting vascular complications in T1D.
There is a correlation between a high level of amyloid-producing Escherichia coli in the intestines and the initiation of autoimmunity and type 1 diabetes progression.
Prebiotic supplementation may serve as an inexpensive and low-risk treatment addition to improve glycemic control in patients with type 1 diabetes.
If approved, it would be the first room temperature stable liquid glucagon in an autoinjector formulation.
Completion of full rotavirus vaccination appears to be associated with a reduction in the risk of type 1 diabetes in children.
Both pediatric and adult patients with type 1 diabetes had favorable outcomes for glycemic control with use of the Omnipod® Insulin Management System.
Dasiglucagon was found to be an effective and safe treatment option for severe hypoglycemia in type 1 diabetes.
Patients who attended complication screenings paid more visits to diabetes clinics within the first 2 years after diagnosis, had higher median lifetime HbA1c, and had less socioeconomic disadvantage.
Closed-loop insulin delivery may mitigate potential changes in glycemic control throughout the menstrual cycle.
In people at high risk of developing type 1 diabetes (T1D), teplizumab may delay or prevent disease progression.
The Omnipod HCL system was safe and performed well in children aged 2 to 6 years with type 1 diabetes.